Smoking-related lung injury may manifest on CT scans as both emphysema and interstitial changes. We have developed an automated method to quantify interstitial changes and hypothesized that this measurement would be associated with lung function, quality of life, mortality, and a mucin 5B (MUC5B) polymorphism.
Smoking-related lung disease may manifest as a variety of parenchymal diseases, including emphysema and fibrosis.
1,2 These features frequently coexist, especially in advanced disease. [3] [4] [5] Visual assessments of CT scans of smokers' lungs have revealed subtle radiologic patterns suggestive of fibrosis, some of which have been termed interstitial lung abnormalities (ILA). 6, 7 These abnormalities are associated with mortality, as well as with a specific single nucleotide polymorphism (rs35705950) in the promoter region of the gene encoding mucin 5B (MUC5B), suggesting that in some cases they may indicate early or mild idiopathic pulmonary fibrosis (IPF). [8] [9] [10] [11] [12] However, ILA are only a subset of the broad range of the nonemphysematous patterns of lung injury evident on the CT scans of smokers, and a more comprehensive assessment of interstitial changes may be required to determine a person's susceptibility to injury from long-term tobacco smoke exposure. 13 We have developed an automated tool that detects and quantifies interstitial and emphysematous features on the lung CT scans of smokers. 14, 15 We hypothesized that interstitial features measured with this tool would be a marker of smoking-related lung injury, and, as such, would be associated with clinically significant measures such as lung function, quality of life, and mortality. In addition, given the ability of this method to detect visually identified ILA we hypothesized that these features would be associated with the presence of the MUC5B promoter polymorphism. Finally, we suspected that visual, spirometric, and clinical-based assessments alone may underestimate disease susceptibility. Therefore, we sought to determine whether the clinical and genetic associations with objective interstitial changes were present in those without visual ILA, in those with normal spirometric test results, and in those without chronic respiratory symptoms.
Methods
We performed our study by using CT scanning and clinical and genetic data from the Genetic Epidemiology of COPD (COPDGene) Study, which has been described in detail elsewhere. 15, 16 Briefly, 10,300 smokers between the ages of 45 and 80 years, with a history of at least 10 pack-years, were enrolled and underwent baseline testing, including an extensive interview, volumetric high-resolution CT scanning of the chest, and spirometric testing. COPDGene excluded Hispanics from the study, and the only two races represented were white and black. Genotyping of the MUC5B promoter polymorphism (rs35705950) was performed (TaqMan Genotyping Assays; Applied Biosystems) as previously described. 8, 10 Participants were excluded if their predominant lung condition was either bronchiectasis or interstitial lung disease (ILD). All participants provided written informed consent, and the overall study was approved by the institutional review boards at all of the participating centers (details available in the online supplement). This specific study was approved by the Partners Human Research Committee, protocol number 2016P001562/BWH.
The objective CT scanning analysis performed in this study has been detailed previously and is described in detail in the online supplement. 14, 15 Briefly, two experts trained the tissue subtype classification tool by placing 33,865 fiducials in 138 randomly selected CT scans on radiographic features unique to each disease subtype: normal, interstitial (reticular, honeycombing, centrilobular nodule, linear scar, nodular, subpleural line, ground glass), and emphysematous (centrilobular and paraseptal). (Note that panlobular emphysema was not identified in the training cases likely because patients with a 1 -antitrypsin disease were not represented in the cohort.) These training points were used to develop tissue classification vectors for each disease subtype, and de novo regions of lung were then classified based on their similarity to these vectors. Using this method, we assigned normal, emphysematous, or interstitial labels to every portion of the lung parenchyma with the results stratified by lung zone (upper, middle, and lower) (Figs 1 and  2 ). The aggregate of these subtype volumes summed to the total lung volume at CT scanning for each patient, and the subtype volumes were expressed as a percentage of total lung volume (ie, percentage normal, percentage emphysematous, and percentage interstitial).
The visual analysis of COPDGene CT scans for ILA has been described elsewhere. 7, 12, 13, 15 An individual's CT scan was determined to have ILA if there were nondependent ground-glass or reticular abnormalities, diffuse centrilobular nodularity, nonemphysematous cysts, honeycombing, or traction bronchiectasis affecting more than 5% of any lung zone. 13 Individuals who had focal or unilateral groundglass attenuation, focal or unilateral reticulation, and patchy groundglass abnormalities (present in less than 5% of the lung) were considered to have indeterminate findings.
Statistical Analysis
We had no a priori hypothesis for the normal range of the percentage of lung occupied by interstitial features. Therefore, for all of the primary analyses, the percentage of interstitial features was evaluated as a continuous variable. Except where stated, in both the primary and subgroup analyses, effect sizes are given per a 5% absolute increase in the percentage of lung occupied by interstitial changes. This scaling was selected because it roughly approximated the SD of Drs Ash and Harmouche contributed equally to this work. Drs San Jose Estepar and Washko contributed equally to this work. interstitial changes in the entire cohort and could be kept stable across subgroups (as opposed to the use of subgroup-specific SDs or quartiles). Secondary analyses, including the analysis of the percentage of interstitial features as a dichotomous variable and by quartiles, and stratification by smoking status can be found in the online supplement.
Univariate and multivariable linear regression were used to evaluate the associations among spirometric test results, St. George's Respiratory Questionnaire (SGRQ) scores, and percentage of interstitial changes, as well as for the association between the number of minor MUC5B alleles and interstitial changes. 17, 18 All linear regression effect sizes are stated as absolute, not relative, differences. Because of known differences in prevalence, genetic analyses were stratified by race. 8 Univariate and multivariable Cox regression were used to evaluate the relationship between interstitial changes and mortality. All of the variables were assessed using the Schoenfeld residuals method, and none violated the proportional hazards assumption. 19 Details regarding the acquisition of mortality data are available in the online supplement.
The multivariable analyses of SGRQ score, MUC5B, and mortality were adjusted for age, sex, race, clinical center, current smoking status, packyears, BMI, percentage of lung occupied by emphysematous changes as determined by means of the objective detection tool, and FEV 1 % predicted. The multivariable analyses of spirometric measures were adjusted for the same covariates with the exception of FEV 1 % predicted.
Subgroup analyses were performed in the following radiographic subsets: subgroup A, which included those without ILA, as well as those with indeterminate findings (ie, this subgroup excluded only those with ILA), and subgroup B, which included only those without ILA (ie, this subgroup excluded both those with indeterminate findings and those with ILA). In addition, subgroup analyses were also performed in those with normal spirometric test results (subgroup C) and in those who did not have chronic respiratory symptoms (subgroup D). Details regarding the subgroup definitions are available in the online supplement (e- Table 1 ). The reported P values are two sided; P values less than .05 were considered to indicate statistical significance, and all analyses were performed using software (SAS 9.4 or JMP 12; SAS Institute).
Results
A total of 8,345 participants had both clinical and objective imaging data available for analysis. Baseline characteristics of the entire cohort and subgroups are shown in Table 1 . The distributions of interstitial changes in the cohort by lung zone are shown in Figure 2 .
As shown in Table 2 , in both the adjusted and unadjusted analyses, increasing amounts of interstitial features were associated with lower FEV 1 % predicted, lower FVC % predicted, higher FEV 1 /FVC ratio, and a worse quality of life as measured with the SGRQ score. Similar findings were present across subgroups with the (Tables 3-6) .
A total of 6,827 participants had mortality data available for analysis. As shown in Table 7 , in the adjusted analyses, for every 5% increase in the percentage of lung occupied by interstitial changes there was a 29% increased risk of death (95% CI, 21-38; P < .001) in all participants. This association was similar across all subgroups.
Finally, and as shown in 
Discussion
In a large cohort of current and former smokers, we found that objectively detected interstitial features were associated with reduced lung function, worse quality of life, and increased mortality. In addition, for each copy of the minor allele of the MUC5B promoter polymorphism (rs35705950), more of the lung was affected by interstitial features. These associations were present even in participants who did not have visually defined ILA, in those with normal lung function, and in those without chronic respiratory symptoms.
There has been increased recognition that smokingrelated lung injury may have important clinical associations, even when patients do not have a disease formally diagnosed. For instance, smokers with clinical symptoms but preserved lung function have more respiratory exacerbations and activity limitation, and they may have increased mortality. [20] [21] [22] In addition, the visual presence of ILA in smokers and former smokers is associated with increased mortality and loss of lung function.
12,23
From an objective imaging standpoint, it has been known for some time that emphysema, measured as the percentage of lung occupied by low-density tissue, is associated with respiratory disease severity. [24] [25] [26] However, it has become increasingly clear that highdensity lung tissue on CT scans, which may indicate inflammation or fibrosis, is also associated with cigarette showed that the quantity of reticular changes objectively identified using a local histogram approach was correlated with pulmonary function test measures and exercise capacity in patients with ILD, and Iwasawa In this study, we found that interstitial features detected and quantified by means of a local histogram-and distance-based method were associated with respiratory disease severity and mortality. These associations were present even in those who were healthy by other metrics, such as visual CT scanning analysis, spirometric test results, and symptoms, suggesting that this method may identify individuals at increased risk for disease who are classified as healthy by means of other screening methods. In addition, a specific polymorphism in the promoter region of MUC5B (rs35705950) known to be associated with ILA and IPF was also associated with interstitial features measured using our technique, suggesting that in some cases these findings may indicate early fibrotic disease. 8, 33 However, in our study, even slight increases in the volume of interstitial features were associated with lower lung function, worse quality of life, and higher mortality, associations unlikely to be entirely explained by early fibrotic lung disease. For instance, those in the second quartile of the percentage of lung with interstitial changes had worse outcomes than those in the first quartile (e- Tables 6 and 7) . One potential explanation for these findings is that interstitial changes detected using this method reflect both early fibrosis and, more broadly, susceptibility to lung injury. This argument is bolstered by the interaction between this measure and smoking status.
Although there was no statistical evidence of effect modification for all clinical associations, in general, interstitial features in current smokers were associated with a smaller effect on outcomes than were those in former smokers (e -Tables 2 and 3 ). Thus, it may be that the presence of these changes in current smokers is, to some extent, a short-term response to tobacco smoke, whereas in former smokers it indicates susceptibility to long-term injury. By combining this approach with clinical characteristics such as smoking status, we may be able to determine which patients are most susceptible to disease and most likely to benefit from new treatment options. In addition, although longitudinal studies are needed to determine whether these features are chestjournal.org associated with lung function decline and mortality over time, if that were the case, then these features could be used as a surrogate end point to monitor disease progression and response to therapy.
Our study has several limitations. These include the use of a single cohort to develop and apply the objective analysis tool and the fact that, although most of the statistical associations were strong, the effect sizes were in some instances relatively small. That said, we believe that subsequent work that combines this tool with other objective imaging features such as body composition and bronchiectasis, as well as with visual radiographic and clinical prediction tools, may result in combinations of findings or scoring systems that have greater relative effects on outcomes. [34] [35] [36] In addition, for the primary
analyses we purposefully chose to analyze our measure of interstitial changes as a continuous variable because we had no a priori hypothesis of a "normal" amount of such changes. Although this allows for a more nuanced measurement of disease severity, it makes the application of this measure to a clinical scenario, in which disease is often defined as present or absent, more challenging. A sample of an approach to dichotomization, and clinical associations by quartile are available in e- Tables 4-7 .
Further work is needed to define better what a normal range is for these features, but other continuous biomarkers of risk have overcome similar challenges. For instance, those in the highest quartile of interstitial features in this study had an 84% higher risk of death than did those in the lowest quartile (95% CI, 1.45-2.32; P < .001) (e- Table 7) , which is similar to the risk for death related to coronary heart disease among those in the highest quartile of serum cholesterol compared with that for those in the lowest quartile (hazard ratio, 1.5-2.3) in the Seven Countries Study. 37 Thus, similar to cardiac disease risk factors that are useful for risk stratification but that do not replace a cardiologist, this imaging tool is not a more sensitive version of a pulmonologist's or radiologist's eye, but rather an adjunct that may be useful for identifying individuals who may be at higher risk for disease.
Finally, there were several outliers in the objective analysis: participants whose CT scans were characterized as having extremely high percentages of interstitial or emphysematous features. As detailed in the online supplement, visual review of these cases revealed that most were participants who had a high BMI or other cause for significant noise in their imaging (e- Table 8 ).
Future work involving both additional training of the detection algorithm and the use of denoising methods will be needed to overcome this issue.
38,39

Conclusions
We have developed and applied an objective analysis tool that quantifies interstitial changes on CT scans to a large cohort of smokers without known interstitial disease. Objective interstitial changes defined by this method were associated with reduced lung function, worse quality of life, and higher mortality, as well as a higher number of copies of a specific polymorphism in the promoter region of MUC5B. Additional work is needed to replicate these findings in other cohorts to help define a normal range of these findings and to determine whether they are associated with change in lung function over time or with other biomarkers.
In addition, although the shared association between objectively measured interstitial changes visible by using this technique and a specific polymorphism in the promoter region of MUC5B known to be associated with both ILA and IPF is intriguing, additional work is needed to understand better the potential biological mechanisms by which these objective findings might be linked to pulmonary fibrosis or other ILDs. Also, because it is unclear whether these findings indicate only very early ILD or some other measure of disease susceptibility, we do not yet know whether their presence indicates that an individual patient should be treated; what effect, if any, that treatment may have on these findings; and whether changes in these findings indicate changes in disease activity or severity over time.
Finally, further work is needed in larger cohorts to determine whether similar findings exist in patients who are healthy in all respects (ie, patients without symptoms who have normal spirometric test results and no visual evidence of ILA). chestjournal.org
